In the fiscal year under review, consolidated net sales increased year-on-year, operating income increased, ordinary income, and profit attributable to owners of the parent decreased.
●Consolidated net sales totaled 198,380 million yen, an increase of 13,574 million yen (7.3%) year-on-year. Sales in the pharmaceuticals business underperformed, while the functional chemicals and safety systems businesses outperformed the previous fiscal year.
●Consolidated operating income totaled 21,505 million yen, an increase of 454 million yen (2.2%) year-on-year, outperforming the previous fiscal year in the pharmaceuticals and safety systems businesses, while underperforming in the functional chemicals industry.
●Consolidated ordinary income totaled 23,025 million yen, a decrease of 128 million yen (0.6%) year-on-year.
●Profit attributable to owners of parent was 14,984 million yen, a decrease of 2,196 million yen (12.8%) year-on-year, owing to recognition of an impairment loss on property, plant, and equipment.

(millions yen)	2014/03	2015/03	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03
Cash flows from operating activities	29,480	20,263	19,603	31,390	20,121	26,803	27,281	24,408	23,141	20,039
Cash flows from investing activities	-20,187	-15,807	-5,090	-11,913	-16,171	-17,694	-17,543	-17,606	-10,641	-15,158
Cash flows from financing activities	5	-12,498	-9,432	-14,103	-6,241	-6,437	-13,894	-8,402	-11,090	-7,950
Cash and cash equivalents at the end of period	50,619	43,374	47,464	51,785	50,532	52,697	46,663	47,483	52,962	53,096